Evaluating the Noninferiority of a new Photodynamic Therapy (FLEXITHERALIGHT) compared with Conventional treatment for Actinic keratosis: Protocol for a Phase 2 Study

F Lecomte Msc, A Vignon-Dewalle, C. Vicentini, E Thecua, P Deleporte, A Duhamel, Serge Mordon, L Mortier

To cite this version:

F Lecomte Msc, A Vignon-Dewalle, C. Vicentini, E Thecua, P Deleporte, et al.. Evaluating the Noninferiority of a new Photodynamic Therapy (FLEXITHERALIGHT) compared with Conventional treatment for Actinic keratosis: Protocol for a Phase 2 Study. JMIR Research Protocols, JMIR publications, 2019. hal-02524558

HAL Id: hal-02524558
https://hal.archives-ouvertes.fr/hal-02524558
Submitted on 30 Mar 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Evaluating the Noninferiority of a new Photodynamic Therapy (FLEXITHERALIGHT) compared with Conventional treatment for Actinic keratosis : Protocol for a Phase 2 Study

F. Lecomte MSc\textsuperscript{1}, AS. Vignon-Dewalle PhD\textsuperscript{1}, C. Vicentini MD\textsuperscript{1,2}, E. Thecua MSc\textsuperscript{1}, P. Deleporte BSc\textsuperscript{1}, A. Duhamel PhD\textsuperscript{2}, S. Mordon PhD\textsuperscript{1} and L. Mortier MD, PhD\textsuperscript{1,2}

\textsuperscript{1}Univ. Lille, INSERM, CHU Lille, U1189 – ONCO-THAI – Image Assisted Laser Therapy for Oncology, F-59000 Lille, France
\textsuperscript{2}Department of Dermatology, CHU Lille, F-59000 Lille, France
\textsuperscript{3}EA 2694-Santé Publique: épidémiologie et qualité des soins, Unité de Biostatistiques, Univ. Lille, CHU Lille, F-59000 Lille, France

Corresponding author: Fabienne LECOMTE
INSERM U1189 ONCO-THAI,
1, Avenue Oscar Lambret,
F-59037 LILLE Cedex,
France
Phone : 33 3 20 44 67 22
E-mail: fabienne.lecomte@inserm.fr

This study is supported by the French National Research Agency (ANR) [Projet-ANR-12-EMMA-0018, http://www.flexitheralight.com/] and sponsored by the University of Lille Hospital (CHU).

Name and contact information for the trial sponsor:

Centre Hospitalier Universitaire de Lille (CHRU of Lille), Direction de la Recherche et de l’Innovation (DRI), 6 Rue Pr Laguesse, 59037 LILLE Cedex, Tél : +33 (0)3 20 44 59 69, Fax : +33 (0)3.20.44.57.11
ABSTRACT

Background

Actinic keratosis (AK) is characterized by pre-invasive, cancerous lesions on sun-exposed skin that negatively affect patient quality of life and may progress to invasive squamous cell carcinoma (SCC). If untreated, AK may either regress or progress to SCC, with significant morbidity and possible lethal outcomes. The most commonly used treatments for AK are cryotherapy, topical chemotherapy and, more recently, photodynamic therapy (PDT). This clinical study is part of a project that aims to create specific light-emitting fabrics (LEFs) that strongly improve the efficiency and reliability of PDT as a treatment for AK.

Objectives

This study aims to compare the efficacy and tolerability of a new PDT protocol involving the Flexitheralight device (N-PDT) with the classic protocol involving the Aktilite CL 128 device (C-PDT; Galderma Laboratories) for the treatment of AK. All participants receive both protocols. The primary objective of this study is to compare the lesion response rate after 3 months of N-PDT with C-PDT. Secondary objectives are evaluations of pain and local tolerance during treatment, the clinical evolution of the subject's skin, and evaluations of patient quality of life and satisfaction.

Methods

The study is a split-face, intraindividual comparison of two PDT protocols. The total number of patients recruited was 42. Patients were exposed to a continuous red light with the Aktilite CL 128 device on one side of the face and to fractionated red illumination with the new device, Flexitheralight, on the other side of the face. Males or females over the age of 18 years with a clinical diagnosis of at least 10 previously untreated, nonpigmented, nonhyperkeratotic grade I and II AK lesions of the forehead and/or scalp were included and were recruited from the Department of Dermatology of the Centre Hospitalier Universitaire de Lille. The patients came to the investigational center for one treatment session (day 1), and they were followed up after 7 days, 3 months and 6 months. A second treatment session was performed on day 111 in cases in which an incomplete response was observed at the 3-month follow-up. Data will be analyzed using SAS software version 9.4 (SAS Institute Inc). Continuous variables will be reported as means and standard deviations, and categorical variables will be reported as frequencies and percentages. The Shapiro-Wilk test will be used to assess the normality of the distribution.

Results: Clinical investigation has been performed. Results are expected to be published at the beginning of 2019.

Conclusions: This phase II clinical trial aims to evaluate the non-inferior efficacy and superior tolerability of N-PDT compared to that of C-PDT. If N-PDT is both efficacious and tolerable, N-PDT could become the treatment of choice for AK, due to its ease of implementation in hospitals.

Registered Report Identifier: N° ID-RCB 2013-A01096-39. Number Clinical Trial (NCT)NCT03076918 https://clinicaltrials.gov/ct2/show/NCT03076918

Keywords: Photodynamic therapy, actinic keratosis, light emitting fabrics, Aktilite CL 128 (Galderma laboratories).
INTRODUCTION

Actinic keratosis (AK) is characterized by common, pre-invasive, cancerous lesions in sun-exposed skin [1-4] that negatively affect the quality of life in patients and may progress to invasive squamous cell carcinoma (SCC) [5].

AK usually develops on areas that are frequently exposed to the sun (e.g., the face, ears, scalp, neck, forearms, and backs of the hands). Patients with AK often express embarrassment, worry, and irritation related to the change in appearance of their skin and the unsightly nature of the lesions [6]. In addition to the emotional strain, AK lesions can be painful and easily traumatised, causing bleeding [5,7-9]. If untreated, AK may either regress or progress to SCC, with significant morbidity and possible lethal outcomes [10]. The malignant potential and the impossibility of predicting which AK lesions will evolve into SCC have led to the common consensus that AK lesions must be treated [11].

The most commonly used treatments for AK are cryotherapy, topical chemotherapy and, more recently, photodynamic therapy (PDT) [2,12-16].

PDT is based on the activation of light-sensitive molecules (photosensitizers) that are preferentially localized in the diseased tissues, resulting in the formation of reactive oxygen species and subsequently tissue injury and cell death. 5-aminolevulinic (ALA) and its ester, methyl aminolevulinate (MAL), are both photosensitizer precursors that are most often used for topical PDT. After topical application to the skin, these photosensitizer precursors are endogenously converted by the heme biosynthetic pathway into the photosensitizer protoporphyrin IX (PpIX) and other intermediate photosensitizing porphyrins [17]. As abnormal cells accumulate substantially higher levels of PpIX than normal cells [18], the subsequent illumination leads to their selective destruction. PDT with MAL (MAL-PDT) has been shown to be an attractive treatment modality for AK because it enables the treatment of large areas with a high response rate and an excellent cosmetic outcome [19-22].

Classical PDT (C-PDT) is already used, but it involves rigid, planar light source devices (like Aktilite C128, Galderma Laboratories) that do not allow the homogeneous illumination of convex surfaces such as the scalp. Therefore, the dermatologist does not know the actual light dose that is delivered during C-PDT, and some lesions may be under-treated. This limitation could explain some treatment failures [23]. Moreover, C-PDT is only available in specialized environments (hospitals and clinics) and has not been sufficiently developed and widely used.

This clinical study is part of a project that aims to create specific light-emitting fabrics (LEFs) that improve the efficiency and reliability of PDT [24] as a treatment for AK. Flexitheralight is a new device for PDT treatment (N-PDT; U1189, Inserm) that appears to be perfectly adapted for treating skin zones because of its homogeneity, low weight, flexibility, optimal conformability, and low cost. Moreover, the Flexitheralight device can be used at home, following the diagnosis and treatment definition by specialists.
METHODS

A. Trial Design
The trial was a proof-of-concept study and was a comparative (split-face and intra-individual comparison), randomized, open-label, single-centre evaluation of the non-inferiority of N-PDT compared to C-PDT.

B. Setting
The study was conducted at the Lille University Hospital in the Department of Dermatology over a period of 24 months, until the end of 2017. Forty-two patients were included and were followed for 6 months.

C. Device
Flexitheralight is a new illumination device consisting of (LEFs) connected to a laser source (Figure 1) for fractionated illumination, 3 juxtaposed LEF, each 20 cm x 5 cm, are positioned on the patient’s head. Each LEF is connected to a 635 nm laser source, which is tuned to deliver an irradiance of 12.3 mW/cm². This irradiance is controlled by a PD300 photodiode sensor connected to a Star Bright laser power meter (Both Ophir Optronics Solutions Ltd).

The 3 LEF are activated sequentially as follows (Figure 2):
- ON for 60 s and OFF for 120 s
- This sequence was repeated 50 times.

When using these parameters, the total fluence is 37 J/cm² for an illumination time of 2 hours and 30 minutes.

Figure 1: Flexitheralight device
Figure 2: Fractionated illumination
D. Participants

To be eligible for the study, patients had to fulfill all the inclusion criteria described in Textbox 1 below. If they had only one of the noninclusion criteria, they were excluded from the study. Information about the trial was provided to the patients, both orally and in a written format. Written informed consent was obtained from patients at the screening visit before entering the study. The tolerability of the device was assessed on the first five patients. The study would have been completely interrupted if at least one patient had pain rated at 5 or higher out of 10 in the N-PDT area as measured by the pain assessment scale or at least one serious adverse event related to N-PDT occurred.

Textbox 1: Inclusion and exclusion criteria

| Inclusion criteria                                      | Males or females over the age of 18 years |
|--------------------------------------------------------|------------------------------------------|
| Clinical diagnosis of at least 10 previously untreated, not-pigmented, non-hyperkeratotic, grade I and II AK of the forehead and/or scalp (according to Olsen et al. JAAD 1991, [25]). |
| Other therapies are not unacceptable or considered medically less appropriate |
| Symmetrical repartition of AK in terms of number and severity of lesions on both areas of the forehead and/or scalp. The axis of symmetry between the two areas is defined by the investigator according to the distribution of lesions. |
| AK is diagnosed upon a clinical evaluation (i.e. visual inspection and palpation) performed by the investigator |
| No treatment of AK received in the previous 30 days |
| The two areas to be treated should not be coalescing. A minimum distance of 10 mm between the lesions located on the 2 symmetrical areas is required. A minimum distance of 2 mm between the lesions on the same area is required. |
| A minimum of 5 lesions and a maximum of 7 lesions with similar dimensions at both symmetrical areas are included. If the number of lesions is >7, only 7 lesions in each area are considered. |

| Exclusion criteria                                      | Patients with porphyria |
|--------------------------------------------------------|-------------------------|
| Immunosuppressed patients for idiopathic, disease specific or therapeutic reasons |
| Use of topical corticosteroids on the lesioned areas within 2 weeks before PDT |
| Patients receiving local treatment (including cryotherapy and curettage-electrocoagulation or any PDT treatment) of the face / scalp area within the last 30 days. |
| Patients receiving topical treatment (including imiquimod, 5-FU, diclofenac and |
ingenol mebutate) of the face / scalp area within the last 3 months.

Use of topical retinoids or alpha-hydroxy acids, urea or systemic retinoids, chemotherapy or immunotherapy within the 4 last weeks

Pigmented AK lesions.

Known allergy to MAL or a similar PDT compound or excipients of the cream including arachis, peanut or soya oil.

Additional exclusion criteria

Participation in other clinical studies either currently or within the last 30 days

Female subjects must meet one of the following criteria:

- Non-childbearing potential, i.e. post-menopausal or have a confirmed clinical history of sterility (e.g. the subject does not have an uterus) or
- Childbearing potential, provided there is a confirmed negative urine pregnancy test or blood analysis prior to study treatment, to exclude pregnancy.

Any condition that may be associated with a risk of poor protocol compliance.

Patients currently receiving regular ultraviolet radiation therapy

### E. Study Objectives / Outcomes

The primary objective is the comparison of the lesion response rate 3 months after either N-PDT or C-PDT. Key secondary objectives are treatment tolerability, complete response rate after 6 months, cosmetic results, patient quality of life, and satisfaction (Textbox2).

**Textbox 2**: Criteria for objectives evaluation

| Outcomes                          | Description                                               | Visits                  |
|-----------------------------------|-----------------------------------------------------------|-------------------------|
| Complete Response Rate            | Total disappearance of each lesion                        | Visit 3, 3 months       |
|                                   |                                                           | Visit 4, 6 months       |
|                                   | Number of patients presenting a 75% lesion reduction rate | Visit 3, 3 months       |
|                                   |                                                           | Visit 4, 6 months       |
| Tolerability                      | Evaluation of pain (Visual Analogical Scale)              | Visit 1, day 1          |
|                                   |                                                           | Visit V3bis, day 111    |
|                                   | Local tolerance (adverse event, serious adverse event, concomitant treatments) | Visit 1, day 1          |
|                                   |                                                           | Visit 2, day 7          |
|                                   |                                                           | Visit V3bis, day 111    |
Cosmetic results

| 4 point scale for the clinical assessment of the subject’s skin aspect (excellent, good, fair or poor) | Visit 1, day 1
| | Visit 3, 3 months
| | Visit 4, 6 months |

Quality of Life & Satisfaction

| DLQI +Questionnaire of satisfaction | Visit 1, day 1
| | Visit 2, day 7
| | Visit V3bis, day 111
| | Visit 3, 3 months
| | Visit 4, 6 months |

**F. Sample Size**

The study is designed to have a statistical power of 80% with a one-sided alpha level of .025 to determine noninferiority in terms of a complete lesion response rate 3 months after N-PDT compared with C-PDT. Assuming a complete lesion response rate of 75% in both areas, an intrapatient correlation in both lesions and areas, and a noninferiority margin of 10%, the number of required lesions per area is 245. This value corresponds to 42 patients, assuming 12 lesions per patient (6 lesions per patient per area).

**G. Allocation/Randomization**

Patients who met all of the eligibility criteria were included in the study by central randomization. The randomization schedule was generated by a statistician using the PROC PLAN procedure in SAS statistical software (SAS Institute Inc) with a 1:1 allocation ratio and a block size of 6. The allocation was concealed using sequentially numbered, opaque, sealed envelopes that were opened sequentially by the investigator at the beginning of the treatment.

**H. Implementation/ Blinding**

The study was not blinded, and patients and investigators knew the procedure allocation. Efficacy and tolerability were evaluated by investigators who knew the type of treatment assigned to each area. Data will also be analyzed without blinding.

**I. Interventions**

As shown in Figure 3, after screening, patients who met all the inclusion criteria and none of the exclusion criteria were randomized and invited to come to the investigation site for 4 visits: day 1, day 7, month 3, and month 6. If an incomplete clinical response was observed at month 3, patients were retreated with PDT during visit 3bis on day 111.
a) Initial Visit: Preparation and Treatment of Lesions

Selection of Treatment Areas

Each subject’s skin aspect was evaluated, and the two areas were treated according to the study protocol and randomization design. Randomization was performed after the definition of the axis of symmetry to avoid selection errors (Figure 4). The global area of the scalp and front of the face was divided into two symmetrical areas (area A and area B) containing the same number and same grades of AK lesions. The areas to be treated were localized between the eyebrows and the neck. Included AK lesions were located, counted, graded, and photographed. For each patient, n lesions in area A were treated with one technique (N-PDT or C-PDT) and n lesions in area B were treated with the other technique (C-PDT or N-PDT) (5≤n≤7).
Before applying MAL, the areas were prepared by removing the crusts with a small curette and gently scraping the surface of the lesions to roughen the surface.

Pain in the two treated areas was scored by the patient after treatment: first for the N-PDT area and then for the C-PDT area.

Patients complete a quality of life questionnaire (Dermatology Life Quality Index [DLQI]) and a satisfaction questionnaire at the end of the procedure.

The total duration of the treatment procedure (treatment of areas A and B) was approximately 3 hours and 20 minutes.

**Area A: Classical Photodynamic Therapy**

MAL was applied (approximately 1 mm thick) with a spatula on the selected lesions and over an area of 5 to 10 mm of normal skin surrounding the lesions. The treated area was covered with an occlusive (Tegaderm, 3M) and light-proof (aluminium foil) dressing for 3 hours. Afterward, the dressing was removed, the area was cleaned with a saline solution, and the skin was then immediately exposed to a continuous red light spectrum delivered by an Aktilite CL 128 device (Galderma Laboratories) (570 to 670 nm) for 10 minutes for a total light dose of 37 J/cm² (Figure 5).

**Area B: New Photodynamic Therapy**

MAL was applied as described for the area A treatment, and the area was covered with an occlusive and transparent dressing (Tegaderm, 3M) for 30 minutes whereas both a transparent occlusive dressing and a light-proof dressing (aluminium foil) was applied over the area randomized to receive C-PDT. Afterward, the dressing was retained, and irradiation was applied with the Flexitheralight device (635 nm) for 2 hours and 30 minutes. A total light dose of 37 J/cm² was administered (Figure 6). After the end of the illumination, area B was protected with aluminium foil.

**Figure 5:** Illustration of the Classical photodynamic therapy treatment procedure

**Figure 6:** Illustration of the New photodynamic therapy treatment procedure
Follow-Up and Retreatment Visits

Visit 2 occurred 7 days after treatment to evaluate the tolerability and adverse effects of the treatments. Patients completed the DLQI and satisfaction questionnaires. Photographs of the treated areas were captured under standardized conditions.

Visit 3 occurred 3 months after treatment. The investigator evaluated the response to treatment by comparing the lesions between the current visit and the first visit (by referring to paper tracings and photographs taken during the first visit). If some of the treated AK lesions remained, a new visit was scheduled within 3 weeks to treat the remaining lesions. The remaining lesions in each area were located, counted, and graded. Only the presence of lesions was considered and not any changes in their sizes. If a new lesion appeared, it was treated (by the same procedure), but it was not considered for the comparison of lesions between months 3 and 6. Photographs of the two treated areas were taken. Patients completed the DLQI and the satisfaction questionnaires, and all adverse events and concomitant medications were recorded. Patients for whom the AK lesions had completely disappeared were invited to participate in an assessment visit at month 6.

Visit 3bis was optional and scheduled only in cases where at least one AK lesion remained after the first treatment session and only if the investigator considered it necessary for the subject to be treated again with PDT. The same treatment was applied as in visit 1.

Visit 4 occurred 6 months after the initial treatment. The investigator evaluated the treatment response by comparing the lesions between the current visit and the first visit. Photographs of the two treated areas were taken. Patients completed the DLQI and the satisfaction questionnaires, and all adverse events and concomitant medications were recorded.

J. Variables/Data Collection

Collected data consisted of demographic data, medical history reviews, previous radiotherapy histories, history of surgery and treatment for AK, definition of AK lesions (localization, number, grade, and photographs), and assessments of the subjects’ skin aspects. For women of childbearing age, a urine pregnancy test was performed at screening or before the beginning of the treatment. Several scales (pain, aesthetic aspect, and treatment tolerance) and questionnaires (DLQI and satisfaction) were used.

K. Data Management

All medical observations were maintained in the patient’s file; the data to be analyzed in the study were reported on an electronic case report form according to Good Clinical Practices and the sponsor’s standard operating procedures. The data collection procedure was exhaustive and verified regularly by a clinical research associate according to the protocol. Any deviation from the protocol was noted, and the reason for the deviation was documented. Discrepancies in the data were brought to the attention of the clinical team and investigational site personnel in the form of a query. Resolutions to these issues are reflected in the database.

L. Statistical Methods

Continuous variables will be reported as the means and standard deviations, and categorical variables will be reported as frequencies and percentages. The Shapiro-Wilk test will be used to assess the normality of the distribution. This normality will also be evaluated graphically.

Analysis of the primary objective

In this study, each patient could have several lesions. We considered the “patient” effect. Indeed, a correlation could exist between the outcome measures in a single patient (cluster effect). The complete response rate of lesions will be analyzed according to the treatment groups (N-PDT or C-PDT) using the generalized linear mixed model to consider the cluster effect with an adjustment for the period (by the area). The 95% confidence interval of the absolute difference in response rates between the two groups will be calculated (D=N-PDT – C-PDT). We will conclude noninferiority if the lower limit of this 95% confidence interval is greater than 10%. If noninferiority is confirmed, a superiority test will be performed.
Analysis of the secondary objectives

The percentage of patients in each group with a reduction in the lesion number greater than 75% will be calculated and compared using a generalized linear mixed model. The aforementioned method will be used for comparisons of the other qualitative variables between the two groups (N-PDT or C-PDT). For continuous variables, we will use the linear mixed model. The pain levels reported at the end of each treatment will be compared using a linear mixed model, with patients as the random effects (the significance level will be set to .05). All statistical analyses will be performed using SAS software version 9.4 (SAS Institute Inc).

M. Ethical Approval

This study was performed in accordance with the ethical principles of the Declaration of Helsinki (2008) and the International Conference on Harmonisation–Good Clinical Practices and in compliance with Article L. 1121-4 of the French Public Health Code. The study design was reviewed and approved by the French National Agency for the Safety of Medicines and Health Products (authorization number 2013-A01096-39) and the French Ethics Committee (authorization number CPP-03/051/2013).

RESULTS

Figure 7 shows the evolution of the number of subjects included, followed, and considered in the statistical analysis. Enrollment is closed. A total of 27 patients were recruited and followed instead of the planned 42 subjects due to the early termination of the Flexitheralight study, resulting from the launch of the competing Phos-Istos European study. Of the 27 patients, 23 completed all visits of the study.

The clinical investigation was performed by July 2018. Data analysis was performed at the end of 2018, and results are expected to be published in early 2019.
Figure 7: Study flow chart. AK: actinic keratosis

Enrollment

Assessed for eligibility (n=27 patients)
Non Included (n=2 patients)
Declined to participate (n=2 patients)

Randomized (n=25 patients, 310 AK lesions)

Treatment Allocation

Allocated to intervention (n=25 patients)
156 AK lesions treated with Flexitheralight
154 AK lesions treated with Aktilite CL128

Follow up Month 3

Follow up (n=25 patients)
156 AK lesions treated with Flexitheralight
154 AK lesions treated with Aktilite CL128
None excluded

Re-Treatment Day 111

Allocated to a new intervention (n=20 patients)
Received Flexitheralight on a ½ area and Aktilite CL128 on the other area with the same randomization as initially

Follow up Month 6

Follow up (n=23 patients)
144 AK lesions with Flexitheralight
142 AK lesions with Aktilite CL128

Excluded (n=2 patients)
Declined to participate (n=1 patient)
Serious Adverse Event not related to procedure (n=1 patient)

Analyse

Analyse (n=23 patients)
None were excluded from the analysis

Randomized (n=25 patients, 310 AK lesions)
DISCUSSION

As part of the primary objective, we hope to demonstrate that N-PDT is not inferior to C-PDT in terms of the lesion response rate at month 3. As part of the secondary objectives, we seek to demonstrate that N-PDT is less painful and better tolerated than C-PDT as a treatment for AK.

The adverse effects associated with C-PDT are usually a local reaction at the treatment site that is attributable to the toxic effects of PDT (phototoxicity) or to the preparation of the lesion. The most common symptoms are pain and discomfort, which are described as burning and stinging sensations, erythema, and encrusting sensations of skin pain. Usually, the symptoms begin with or immediately after illumination, last for a few hours, and disappear on the day of treatment.

The possible risks related to N-PDT have been analyzed. Based on the results from this analysis, the Flexitheralight device has been classified as an exempt risk group, according to International Electrotechnical Commission 60601-2-57/2012.

Regarding the irradiance, the objective was to deliver 12.3 mW/cm², lower than the 75 mW/cm² irradiance delivered by the Aktilite CL 128 device or the 22 mW/cm² delivered by sunlight at midday in the summer in Munich. The expected benefit for patients included in the study is a reduction of pain experienced during treatment, increasing comfort. Indeed, illumination during C-PDT is intensively administered for a short period of time, which is known to increase pain [26].

In addition to the impact on pain, the flexibility of the Flexitheralight device enables a homogeneous illumination, which should yield better efficiency. Moreover, N-PDT could be performed in all weather conditions, in any geographic location, year round, and could therefore become the treatment of choice for AK

ACKNOWLEDGEMENTS

The authors wish to thank all research and medical personnel involved in the design and execution of this study. This study is supported by the French National Research Agency (Projet-ANR-12-EMMA-0018, www.flexitheralight.com) and sponsored by the Centre Hospitalier Universitaire de Lille. Galderma International graciously provided Metvixia (the form of MAL used in the intervention),

AUTHORS’ CONTRIBUTION

Pr. L. Mortier, the principal investigator, designed the study and critically reviewed and approved the protocol. Dr. C. Vicentini drafted the manuscript and selected and followed patients. AS. Vignion Dewalle, E. Thecua, P. Deleporte helped by revising the protocol, participating in the conception of the study, and performing technical maintenance of the device. Pr. S. Mordon critically reviewed and approved the final manuscript for publication. A. Duhamel wrote the statistical analysis plan, and his unit will analyze the results of the study.

CONFLICT OF INTEREST

Dr Claire Vicentini received travel grants and accommodation expenses from Galderma International to attend the 16th Annual Congress of the European Society for Photodynamic Therapy in Munich, Germany, February 10-11, 2017. All other authors have no conflicts of interest to declare.

REFERENCES
1. IBRAHIM SF, BROWN MD. ACTINIC KERATOSES: A COMPREHENSIVE UPDATE. J CLIN AESTHET DERMATOL 2009 JUL;2(7):43-48 [MEDLINE: 20729970]

2. SZEIMIES RM, TOREZAN L, NIWA A, VALENTE N, UNGER P, KOHL E, ET AL. CLINICAL, HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL ASSESSMENT OF HUMAN SKIN FIELD CANCERIZATION BEFORE AND AFTER PHOTODYNAMIC THERAPY. BR J DERMATOL 2012 JUL;167(1):150-159. [DOI: 10.1111/J.1365-2133.2012.10887.x] [MEDLINE: 22329784]

3. FABBROCINI G, TRIASSI M, MAUERIELLO MC, TORRE G, ANNUNZIATA MC, DE VITA V, ET AL. EPIDEMIOLOGY OF SKIN CANCER: ROLE OF SOME ENVIRONMENTAL FACTORS. CANCERS (BASEL) 2010 NOV 24;2(4):1980-1989 [FREE FULL TEXT] [DOI: 10.3390/CANCERS2041980] [MEDLINE: 22482121]

4. DE OLIVEIRA ECV, DA MOTA VRV, PANTOJA PC, ILHA OSDO, MAGALHÃES RF, GALADARI H, ET AL. ACTINIC KERATOSIS—REVIEW FOR CLINICAL PRACTICE. INT J DERMATOL 2018 AUG 02 [FREE FULL TEXT] [DOI: 10.1111/ijd.14147] [MEDLINE: 30070357]

5. ESMAIN M, JEMEG GB. MANAGEMENT OF ACTINIC KERATOSIS PATIENTS: A QUALITATIVE STUDY. J DERMATOL TREAT 2007;18(1):53-58. [DOI: 10.1080/09546630601028737] [MEDLINE: 17365267]

6. EINSPARJ JG, STRATTON SP, BOWDEN GT, ALBERTS DS. CHEMOPREVENTION OF HUMAN SKIN CANCER. CRIT REV ONCOL HEMATOL 2002 MAR;41(3):269-285. [MEDLINE: 11880204]

7. THAI K, FERGIN P, FREEMAN M, VINCIULLO C, FRANCIS D, SPELMAN L, ET AL. A PROSPECTIVE STUDY OF THE USE OF CRYOSURGERY FOR THE TREATMENT OF ACTINIC KERATOSES. INT J DERMATOL 2004 SEP;43(9):687-692. [DOI: 10.1111/J.1365-4632.2004.02056.x] [MEDLINE: 15357755]

8. HOLMES C, FOLEY P, FREEMAN M, CHONG AH. SOLAR KERATOSIS: EPIDEMIOLOGY, PATHOGENESIS, PRESENTATION AND TREATMENT. ASTRALAS J DERMATOL 2007 MAY;48(2):67-74. [DOI: 10.1111/J.1440-0960.2007.00339.x] [MEDLINE: 17535191]

9. CANTISANI C, DE GADO F, ULRICH M, BOTTONI U, IACOBELLIS F, RICHETTA AG, ET AL. ACTINIC KERATOSIS: REVIEW OF THE LITERATURE AND NEW PATENTS. RECENT PAT INFLAMM ALLERGY DRUG DISCOV 2013 MAY;7(2):168-175. [MEDLINE: 23470197]

10. FERNANDEZ FMT. FROM ACTINIC KERATOSES TO SQUAMOUS CELL CARCINOMA: PATHOPHYSIOLOGY REVISITED. J EUR ACAD DERMATOL VENEREOLOGIE 2017 MAR;31 SUPPL 2:5-7. [DOI: 10.1111/JVD.14151] [MEDLINE: 28263020]

11. STOCKFLETH E, FERRANDIZ C, GROB JJ, LEIGH I, PEHAMBERGER H, KERL H. EUROPEAN SKIN ACADEMY. DEVELOPMENT OF A TREATMENT ALGORITHM FOR ACTINIC KERATOSES: A EUROPEAN CONSENSUS. EUR J DERMATOL 2008;18(6):651-659. [DOI: 10.1684/EJD.2008.0514] [MEDLINE: 18955209]

12. SCHMITZ L, OSTER-SCHMIDT C, STOCKFLETH E. NONMELANOMA SKIN CANCER—FROM ACTINIC KERATOSES TO CUTANEOUS SQUAMOUS CELL CARCINOMA. J DTSCH DERMATOL GES 2018 AUG;16(8):1002-1013 [FREE FULL TEXT] [DOI: 10.1111/DDG.13614] [MEDLINE: 30117703]

13. BRAATHEN LR, SZEIMIES R, BASSET-SEGUIN N, BISSONNETTE R, FOLEY P, PARISER D, INTERNATIONAL SOCIETY FOR PHOTODYNAMIC THERAPY IN DERMATOLOGY. GUIDELINES ON THE USE OF PHOTODYNAMIC THERAPY FOR NONMELANOMA SKIN CANCER: AN INTERNATIONAL CONSENSUS. INTERNATIONAL SOCIETY FOR PHOTODYNAMIC THERAPY IN DERMATOLOGY. 2005. J AM ACAD DERMATOL 2007 JAN;56(1):125-143. [DOI: 10.1016/J.JAAD.2006.08.006] [MEDLINE: 17190630]

14. MORTON CA, MCKENNA KE, RHODES LE. BRITISH ASSOCIATION OF DERMATOLOGISTS THERAPY GUIDELINES AND AUDIT SUBCOMMITTEE. GUIDELINES FOR TOPICAL PHOTODYNAMIC THERAPY: UPDATE. BR J DERMATOL 2008 DEC;159(6):1245-1266. [DOI: 10.1111/J.1365-2133.2008.08882.X] [MEDLINE: 18945319]

15. MORTON C, SZEIMIES R, SIDOROFF A, WENNBERG A, BASSET-SEGUIN N, CALZAVARA-PINTON P, EUROPEAN DERMATOLOGY FORUM. EUROPEAN DERMATOLOGY FORUM GUIDELINES ON TOPICAL PHOTODYNAMIC THERAPY. EUR J DERMATOL 2015;25(4):296-311. [DOI: 10.1684/EJD.2015.2570] [MEDLINE: 26065545]

16. WIEGELL SR. UPDATE ON PHOTOODYNAMIC TREATMENT FOR ACTINIC KERATOSIS. CURR PROBL DERMATOL 2015;46:122-128. [DOI: 10.1159/000366548] [MEDLINE: 25561216]

17. FRENCH SOCIETY OF DERMATOLOGY. [GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CUTANEOUS SQUAMOUS CELL CARCINOMA AND PRECURSOR LESIONS. ARGUMENTS—MAY 2009]. ANN DERMATOL VENEREOLOGIE 2009 SEP;136 SUPPL 5:S189-S242. [MEDLINE: 19795558]

18. KENNEDY JC, POTTIER RH. ENDOGENOUS PROTOPYRPHORIN IX, A CLINICALLY USEFUL PHOTOSENSITIZER FOR PHOTODYNAMIC THERAPY. J PHOTOCHEM PHOTOBIIOL B 1992 JUL 30;14(4):275-292. [MEDLINE: 1403373]

19. MORTON CA, SZEIMIES R, SIDOROFF A, BRAATHEN LR. RESPONSE TO LETTER TO THE EDITOR: EUROPEAN GUIDELINES FOR TOPICAL PDT PART 1. J EUR ACAD DERMATOL VENEREOLOGIE 2015 JUL;29(7):1451-1452. [DOI: 10.1111/JVD.12506] [MEDLINE: 24666245]

20. MORTON C, CAMPBELL S, GUPTA G, KEOHANE S, LEAR J, ZAKI I, AKTION INVESTIGATORS. INTRAINDIVIDUAL, RIGHT-LEFT COMPARISON OF TOPICAL METHYL AMINOLAELAVULINATE-PHOTODYNAMIC THERAPY AND CRYOTHERAPY IN SUBJECTS WITH ACTINIC KERATOSES: A MULTICENTRE, RANDOMIZED
CONTROLLED STUDY. BR J DERMATOL 2006 NOV;155(5):1029-1036. [DOI: 10.1111/j.1365-2133.2006.07470.x] [MEDLINE: 17034536]

21. PARISER D, LOSS R, JARRATT M, ABRAMOVITS W, SPENCER J, GERONEMUS R, ET AL. TOPICAL METHYL-AMINOLEVULINATE PHOTODYNAMIC THERAPY USING RED LIGHT-EMITTING DIODE LIGHT FOR TREATMENT OF MULTIPLE ACTINIC KERATOSES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. J AM ACAD DERMATOL 2008 OCT;59(4):569-576. [DOI: 10.1016/j.jaad.2008.05.031] [MEDLINE: 18707799]

22. SZEIMIES R, MATHÉSON RT, DAVIS SA, BHATIA AC, FRAMBACH Y, KLÖVEKORN W, ET AL. TOPICAL METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY USING RED LIGHT-EMITTING DIODE LIGHT FOR MULTIPLE ACTINIC KERATOSES: A RANDOMIZED STUDY. DERMATOL SURG 2009 APR;35(4):586-592. [DOI: 10.1111/j.1524-4725.2009.01096.x] [MEDLINE: 19309347]

23. MOSELEY H. LIGHT DISTRIBUTION AND CALIBRATION OF COMMERCIAL PDT LED ARRAYS. PHOTOCHM PHOTOBiol SCI 2005 NOV;4(11):911-914. [DOI: 10.1039/b507325a] [MEDLINE: 16252048]

24. MORDON S, COCHRANE C, TYLCZ JB, BETROUNI N, MORTIER L, KONCAR V. LIGHT EMITTING FABRIC TECHNOLOGIES FOR PHOTODYNAMIC THERAPY. PHOTODIAGNOSIS PHOTODYN THER 2015 MAR;12(1):1-8 [FREE FULL TEXT] [DOI: 10.1016/j.pdpdt.2014.11.002] [MEDLINE: 25481663]

25. OLSEN EA, ABERNETHY ML, KULP-SHORTEN C, CALLEN JP, GLAZER SD, HUNTLEY A, ET AL. A DOUBLE-BLIND, VEHICLE-CONTROLLED STUDY EVALUATING MASOPROCOL CREAM IN THE TREATMENT OF ACTINIC KERATOSES ON THE HEAD AND NECK. J AM ACAD DERMATOL 1991 MAY;24(5 PT 1):738-743. [MEDLINE: 1869646]

26. APALLA Z, SOTIRIOU E, PANAGIOTIDOU D, LEFAKI I, GOUSSI C, IOANNIDES D. THE IMPACT OF DIFFERENT FLUENCE RATES ON PAIN AND CLINICAL OUTCOME IN PATIENTS WITH ACTINIC KERATOSES TREATED WITH PHOTODYNAMIC THERAPY. PHOTODERMATOL PHOTOIMMUNOL PHOTOMED 2011 AUG;27(4):181-185 [FREE FULL TEXT] [DOI: 10.1111/j.1600-0781.2011.00595.x] [MEDLINE: 21729165]

ABBREVIATIONS

AK Actinic Keratosis
ALA Aminolevulinic Acid
C-PDT Classical Photodynamic Therapy
DLQI Dermatology Life Quality Index
E-CRF Electronic Case Report Form
LEF Light Emitting Fabrics
MAL Ester Methyl Aminolevulinate
N-PDT New Photodynamic Therapy
PDT Photodynamic Therapy
PpIX Protoporphyrin IX
SCC Squamous Cell Carcinoma